SEC Form 4 · accession 0001179110-16-026503
IDERA PHARMACEUTICALS, INC. · IDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
James A Geraghty
Director
Period of report
Jun 13, 2016
Accepted (ET)
Jun 15, 2016 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | $1.44 | Jun 13, 2016 | A | 52,000 | A | — | Jun 13, 2026 | Common Stock | 52,000 | 52,000 | D |
Explanation of responses
- F1The option was automatically granted pursuant to the Company's director compensation program on the date of the Company's 2016 annual meeting of stockholders at an exercise price equal to the closing price of the Company's common stock on the date of grant.
- F2The options vests with respect to one third of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in eight equal quarterly installments following the first anniversary of the date of grant, subject to continued service as a director, and are granted under our 2013 Stock Incentive Plan